Median Diagnosis-to-Treatment Interval of 15 Days in Registry of 2,610 Patients With Diffuse Large B-Cell Lymphoma
A registry study published November 14 in Scientific Reports examined the relationship between the diagnosis-to-treatment interval and survival in diffuse large B-cell lymphoma. The authors, Alem, Mohanty, Pati, and colleagues, included 2,610 patients treated with immunochemotherapy.
The median interval from diagnosis to treatment was 15 days, with an interquartile range of 8 to 28 days. Patients treated within 14 days had more adverse features, including stage III or IV disease, poor performance status, elevated LDH, B symptoms, bulky disease, more than one extranodal site, and anemia.
In unadjusted analyses, a shorter interval was associated with worse overall and progression-free survival. After IPTW adjustment, a short interval was instead associated with better overall survival, with an adjusted hazard ratio of 0.68 and a 95 percent confidence interval of 0.52 to 0.88. The authors conclude that a short interval should be read mainly as a marker of disease severity rather than as an adverse prognostic factor in itself.
Source: Scientific
Published by GSM · USA (original Chinese edition)
Photo: 图：淋巴结的结构示意图，显示淋巴液的流入与流出路径。来源：SEER / U.S. National Cancer Institute，Wikimedia Commons，Public domain。 / Photo: Diagram of the structure of a lymph node, showing lymph inflow and outflow. Source: SEER / U.S. National Cancer Institute, Wikimedia Commons, Public domain.
